{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 38,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to highlight key value propositions of the Olvi-Vec technology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/4",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.72,
        "y": 0.25
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fc6998f-4804-43df-afe8-5e8c76e34e2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.13,
        "y": 0.25
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8be61602-2cf3-4127-8ae1-cd6288b0d886",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.42,
        "y": 0.25
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4daed67-975e-4084-a4fe-b3fc4c14d9d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.06,
        "y": 0.58
      },
      "kind": "list",
      "text": "Regional and systemic administration to preferentially locate, colonize and destroy tumor cells. In Ovarian Cancer trials, catheter placement is prior to chemotherapy, with removal 2 days after initial placement. IV therapy currently being used in small cell lung cancer Phase 1 trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c60f732-a820-4cbb-8171-847bf189bc1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.36,
        "y": 0.58
      },
      "kind": "list",
      "text": "Strong data in Phase 1b/2 study in platinum-resistant/refractory ovarian cancer (PRROC). No Maximum Tolerated Dose (MTD) observed+. Potential utility in multiple cancers (demonstrated in 20 pre-clinical tumor models), including metastatic disease.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "260319ab-3aec-439a-8e13-8af59ec7e28a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.66,
        "y": 0.58
      },
      "kind": "list",
      "text": "Turns tumors “hot” by localized inflammation and induction of the influx of tumor infiltrating lymphocytes (TILs). Positively modulates anti-tumor pathways in tumor microenvironment.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9a41b7e-8468-4509-8278-0d347fb142d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.64,
        "x": 0.18,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Olvi-Vec: Engineered to selectively target and eliminate tumor cells while inducing a robust patient-specific immune response",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac4d4302-0fc3-4d4e-b5ea-21421a53283c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.06,
        "y": 0.48
      },
      "kind": "title",
      "text": "Physician-preferred Routes of Delivery",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69cb9037-ad65-45b1-8709-828af1b17747",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "The Most Advanced Non-local Delivery Oncolytic Immunotherapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "addff008-fd84-4cfd-9b7c-0480bf26ed96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.36,
        "y": 0.48
      },
      "kind": "title",
      "text": "Antitumor Effect and Well Tolerated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c300c9a3-5b0b-4ad1-91ed-c0f7d838f38c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.66,
        "y": 0.48
      },
      "kind": "title",
      "text": "Ideal Backbone of Combination Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1205397-c783-4379-b86a-a0e02c5a7444",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 4,
      "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5",
      "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.",
      "position": 0,
      "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}